From tanning to PT-141: an unlikely route to Rx
An annotated history of a molecule whose destination was not its starting point.
The tanning project had another effect
The historical account by Hadley and Dorr places PT-141 in the lineage of melanotan-II, a synthetic melanocortin peptide first explored for tanning. Sexual effects during that work prompted development toward sexual function. PT-141 is a distinct structural relative of melanotan-II.
I like an origin that makes the later side effects less surprising. Pigmentation did not disappear from the biology simply because development changed direction: the bremelanotide label still warns about darkening of skin and mucous membranes with frequent exposure. That connection between origin and present-day caution leaves the question of interchangeable risks unanswered.
2003 and 2004: early animal and human studies
The 2003 pharmacology report combined evidence from rats, nonhuman primates and early work in men with erectile dysfunction. It described dose-dependent erectile activity and hypothalamic neuronal activation. A 2004 investigational-drug profile presented PT-141 as a nasal spray for erectile dysfunction and female sexual dysfunction, with a completed Phase IIb erectile-dysfunction trial and Phase III plans.
Meanwhile, the 2004 female-rat study isolated a change in desire-driven solicitation, without a change in reflexive sexual behaviour or motor activity. I read these early papers as a set of possible destinations, rather than as an approval already waiting to happen. The nasal route was later dropped because the absorbed amount varied too much between doses; the dosage page returns to that route distinction.
2019: RECONNECT and US approval
The RECONNECT report supplied the pivotal comparison in premenopausal women with HSDD. Both Phase 3 trials met their desire and distress endpoints. The first-approval review records the United States approval in June 2019 for that indication, using the generic name bremelanotide.
The long-term extension added follow-up rather than a broader approved population. I distrust histories that turn the ending into evidence that every earlier possibility succeeded. Male erectile dysfunction remained outside the approval, as did postmenopausal use and performance enhancement. The name PT-141 can recall the early development programme while the label answers a much narrower question.
2022 and 2025: brain imaging and hamster reward findings
The 2022 human brain-imaging study linked MC4R agonism to changes in sexual-cue processing and reported increased desire for up to 24 hours in premenopausal women with HSDD. The 2025 female Syrian hamster study did not find enhanced sexual reward in its behavioural test.
That awkward pairing is a strength, to my mind. A positive human desire result and a negative animal reward result are not competing scores for the same contest. They concern different outcomes, species and experimental settings. Wanting, arousal and PT-141 follows that disagreement more closely; the reading list includes the original papers rather than only the approval story.